

From: Morris, Nevitt
To: Jennifer.Wellman@sparktx.com
Cc: Morris, Nevitt; jim.wang@sparktx.com; paul.gil@sparktx.com
Subject: BLA 125610 Information Request CMC (7.17.17)
Date: Friday, July 21, 2017 4:12:28 PM
Attachments:
(File Attachment comment)
image001.png

Hi Jennifer:

1.

Please provide the detailed manufacturing and testing information of the "Diluent" (180 mM NaCl, 10 mM sodium phosphate, 0.001% (b) (4) P188, pH (b) (4), (b) (4)), used to dilute (b) (4)

Filtration step. Please clarify if there is any difference in source/supplier, composition, preparation, formulation and qualification of the buffer used as the "Diluent" to formulate the drug substance at Spark and that used for manufacturing the "Drug Product Diluent" at (b) (4).

2.

Please provide the following testing data with pictures in figures for the (b) (4) and Drug Product Lot (b) (4):

a.

Purity by (b) (4);

b.

(b) (4) Protein Identification by (b) (4);

c.

Gene Product Expression by (b) (4) Assay.

3.

Please provide the SOPs for qualification of your key starting materials/reagents, including but not limited to the following:

a. Cell banks

b. Plasmid DNAs

c. FBS

The information should describe how each of these materials are received in your

GMP facility, quarantined, tested, and stored at your site. Please specify the in-house

testing that is performed at your site to confirm the identity, purity and potency of

these materials.

4.

Please clarify if there are any animal-derived reagents/ materials besides the Fetal

Bovine Serum, used for drug substance or drug product manufacturing.

5.

Please specify the CTD section that contains the table of all raw materials used in manufacturing of the drug substance and drug product. If this is not in the BLA please provide a table that lists all raw materials/ reagents used to in manufacture of the drug substance and drug product. This table should include:

- a. Reagent name
- b. Vendor/Supplier
- c. Source (human, bovine, recombinant, etc.);
- d. If animal-derived, identify source organism and country of origin

(Unsigned signature field (Click to sign)) Signature field is unsigned

- e. Grade (licensed product, clinical grade, research grade, etc.)
- f. Final concentration
- g. Certificate of Analysis (CoA)
- h. Purpose or step used in manufacturing

6.

Please describe the purification process for the plasmids from (b) (4) .

Specify which

materials are dedicated to your product vs repeat use, and validation of any cleaning

procedures for columns and other materials that are used for multiple products.

Additionally, please specify which identity test for the plasmids are completed by

(b) (4) , which are completed by Spark and or other contracted sites and describe the

ability of each test to detect contaminating plasmids present at low concentrations and

the limit of detection for each test.

Thanks,

Nevitt

Nevitt Morris

Nevitt

Morris,

RN,

BSN,

BS

Consumer

Safety

Officer

Office

of

Tissues

and

Advanced

Therapies

Center

for

Biologics

Evaluation

and

Research

(CBER)

U.S.

Food

and

Drug

Administration

Building

71,

Room
4207
10903
New
Hampshire
Avenue
Silver
Spring,
MD 20993
Phone: (240)
402-8269
Fax: (301)
595-1303
Nevitt.Morris@fda.hhs.gov

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS
ADDRESSED
AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND
PROTECTED
FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person
authorized to deliver
the document to the addressee, you are hereby notified that any review,
disclosure,
dissemination, copying, or other action based on the content of this
communication is not

authorized. If you have received this document in error, please
immediately notify the sender
immediately by e-mail or phone. immediately by e-mail or phone.